Swiss National Bank lowered its stake in C.R. Bard Inc. (NYSE:BCR) by 2.0% during the third quarter, according to its most recent 13F filing with the SEC. The firm owned 363,761 shares of the company’s stock after selling 7,400 shares during the period. Swiss National Bank owned approximately 0.49% of C.R. Bard worth $81,584,000 as of its most recent filing with the SEC.

Several other hedge funds have also recently modified their holdings of the company. Sentry Investment Management LLC boosted its stake in shares of C.R. Bard by 6.0% in the third quarter. Sentry Investment Management LLC now owns 5,706 shares of the company’s stock valued at $1,280,000 after buying an additional 324 shares during the period. Global X Management Co. LLC raised its stake in C.R. Bard by 90.1% in the third quarter. Global X Management Co. LLC now owns 1,247 shares of the company’s stock valued at $280,000 after buying an additional 591 shares during the last quarter. Icon Advisers Inc. Co. bought a new stake in C.R. Bard during the third quarter valued at $449,000. Signature Estate & Investment Advisors LLC raised its stake in C.R. Bard by 80.7% in the third quarter. Signature Estate & Investment Advisors LLC now owns 1,375 shares of the company’s stock valued at $308,000 after buying an additional 614 shares during the last quarter. Finally, Daiwa Securities Group Inc. raised its stake in C.R. Bard by 6.0% in the third quarter. Daiwa Securities Group Inc. now owns 12,280 shares of the company’s stock valued at $2,754,000 after buying an additional 700 shares during the last quarter. 86.74% of the stock is currently owned by institutional investors and hedge funds.

Institutional Ownership by Quarter for C.R. Bard (NYSE:BCR)

C.R. Bard Inc. (NYSE:BCR) opened at 210.96 on Tuesday. The company has a market cap of $15.51 billion, a P/E ratio of 31.86 and a beta of 0.67. The stock’s 50 day moving average price is $216.43 and its 200-day moving average price is $222.44. C.R. Bard Inc. has a 52-week low of $172.21 and a 52-week high of $239.43.

C.R. Bard (NYSE:BCR) last issued its quarterly earnings results on Tuesday, October 25th. The company reported $2.64 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $2.55 by $0.09. The firm had revenue of $941.90 million for the quarter, compared to analyst estimates of $931.66 million. C.R. Bard had a return on equity of 48.13% and a net margin of 14.05%. The business’s revenue was up 8.8% on a year-over-year basis. During the same period in the previous year, the company posted $2.28 earnings per share. On average, equities analysts predict that C.R. Bard Inc. will post $10.27 earnings per share for the current fiscal year.

The business also recently disclosed a quarterly dividend, which was paid on Friday, November 4th. Investors of record on Monday, October 24th were given a dividend of $0.26 per share. The ex-dividend date was Thursday, October 20th. This represents a $1.04 dividend on an annualized basis and a yield of 0.49%. C.R. Bard’s payout ratio is 15.48%.

ILLEGAL ACTIVITY NOTICE: “Swiss National Bank Sells 7,400 Shares of C.R. Bard Inc. (BCR)” was reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this piece of content on another website, it was illegally copied and reposted in violation of US & international trademark and copyright law. The correct version of this piece of content can be viewed at https://www.thecerbatgem.com/2016/11/29/swiss-national-bank-sells-7400-shares-of-c-r-bard-inc-bcr.html.

Several research firms recently weighed in on BCR. Jefferies Group restated a “hold” rating and set a $237.00 price target on shares of C.R. Bard in a report on Tuesday, September 27th. Wells Fargo & Co. upgraded C.R. Bard from a “market perform” rating to an “outperform” rating in a report on Friday, September 16th. Zacks Investment Research lowered C.R. Bard from a “buy” rating to a “hold” rating in a report on Thursday, August 4th. Evercore ISI began coverage on C.R. Bard in a report on Thursday, September 15th. They set a “buy” rating and a $235.00 price target on the stock. Finally, BMO Capital Markets upgraded C.R. Bard from a “market perform” rating to an “outperform” rating and set a $240.00 price target on the stock in a report on Wednesday, October 26th. They noted that the move was a valuation call. Nine investment analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. The company presently has an average rating of “Hold” and a consensus price target of $233.07.

In related news, Chairman Timothy M. Ring sold 110,000 shares of C.R. Bard stock in a transaction that occurred on Monday, September 26th. The stock was sold at an average price of $228.96, for a total transaction of $25,185,600.00. Following the transaction, the chairman now owns 96,030 shares in the company, valued at $21,987,028.80. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, Chairman Timothy M. Ring sold 92,293 shares of C.R. Bard stock in a transaction that occurred on Wednesday, September 28th. The stock was sold at an average price of $227.81, for a total value of $21,025,268.33. Following the transaction, the chairman now owns 145,876 shares in the company, valued at approximately $33,232,011.56. The disclosure for this sale can be found here. Corporate insiders own 0.97% of the company’s stock.

About C.R. Bard

C. R. Bard, Inc (Bard) and its subsidiaries are engaged in designing, manufacturing, packaging, distribution and sale of medical, surgical, diagnostic and patient care devices. The Company sells its products to hospitals, individual healthcare professionals, extended care facilities and alternate site facilities.

5 Day Chart for NYSE:BCR

Receive News & Stock Ratings for C.R. Bard Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for C.R. Bard Inc. and related stocks with our FREE daily email newsletter.